<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445352</url>
  </required_header>
  <id_info>
    <org_study_id>DP-CTR207-III-02</org_study_id>
    <nct_id>NCT02445352</nct_id>
  </id_info>
  <brief_title>Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia</brief_title>
  <acronym>ROSE</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R207 (Rosuvastatin /Ezetimibe Combination) and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alvogen Korea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alvogen Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of DP-R207 in patients with
      primary hypercholesterolemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline to 8 weeks in LDL-Cholesterol</measure>
    <time_frame>baseline and 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to 4 weeks in LDL-Cholesterol</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to 4 weeks in lipid related blood test results</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to 8 weeks in lipid related blood test results</measure>
    <time_frame>baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching treatment goals according to NCEP ATP III Guideline</measure>
    <time_frame>week 4 and week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">379</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin 5mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once a day, administration of rosuvastatin 5mg and two types of placebo for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DP-R207 5/10mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once a day, administration of DP-R207 5/10mg and two types of placebo for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 10mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once a day, administration of rosuvastatin 10mg and two types of placebo for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DP-R207 10/10mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once a day, administration of DP-R207 10/10mg and two types of placebo for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 20mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once a day, administration of rosuvastatin 20mg and two types of placebo for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DP-R207 20/10mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once a day, administration of DP-R207 20/10mg and two types of placebo for 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 5mg</intervention_name>
    <arm_group_label>Rosuvastatin 5mg &amp; Placebo &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DP-R207 5/10mg</intervention_name>
    <arm_group_label>DP-R207 5/10mg &amp; Placebo &amp; Placebo</arm_group_label>
    <other_name>Rosuvastatin 5mg</other_name>
    <other_name>Ezetimibe 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 10mg</intervention_name>
    <arm_group_label>Rosuvastatin 10mg &amp; Placebo &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DP-R207 10/10mg</intervention_name>
    <arm_group_label>DP-R207 10/10mg &amp; Placebo &amp; Placebo</arm_group_label>
    <other_name>Rosuvastatin 10mg</other_name>
    <other_name>Ezetimibe 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg</intervention_name>
    <arm_group_label>Rosuvastatin 20mg &amp; Placebo &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DP-R207 20/10mg</intervention_name>
    <arm_group_label>DP-R207 20/10mg &amp; Placebo &amp; Placebo</arm_group_label>
    <other_name>Rosuvastatin 20mg</other_name>
    <other_name>Ezetimibe 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)</intervention_name>
    <arm_group_label>Rosuvastatin 10mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_label>DP-R207 10/10mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_label>Rosuvastatin 20mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_label>DP-R207 20/10mg &amp; Placebo &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)</intervention_name>
    <arm_group_label>Rosuvastatin 5mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_label>DP-R207 5/10mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_label>Rosuvastatin 20mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_label>DP-R207 20/10mg &amp; Placebo &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)</intervention_name>
    <arm_group_label>Rosuvastatin 5mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_label>DP-R207 5/10mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_label>Rosuvastatin 10mg &amp; Placebo &amp; Placebo</arm_group_label>
    <arm_group_label>DP-R207 10/10mg &amp; Placebo &amp; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged over 19 years

          -  Signed informed consent form

          -  At visit 1 and visit 2, LDL-Cholesterol ≤ 250mg/dL and Triglyderide ≤ 350mg/dL

        Exclusion Criteria:

          -  Has a history of hypersensitivity to HMG-CoA reductase inhibitor and component of
             ezeimibe

          -  Liver transaminases &gt; 2 x upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yangsoo Jang, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seodaemun-gu</city>
        <state>Seoul</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <last_update_submitted>May 14, 2015</last_update_submitted>
  <last_update_submitted_qc>May 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

